

# Linda R Gowing

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6761693/publications.pdf>

Version: 2024-02-01

50  
papers

3,176  
citations

257357

24  
h-index

330025

37  
g-index

52  
all docs

52  
docs citations

52  
times ranked

4286  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	1.7	685
2	Global statistics on addictive behaviours: 2014 status report. <i>Addiction</i> , 2015, 110, 904-919.	1.7	311
3	Oral substitution treatment of injecting opioid users for prevention of HIV infection. <i>The Cochrane Library</i> , 2011, , CD004145.	1.5	197
4	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016, , CD011117.	1.5	148
5	Psychosocial interventions for cannabis use disorder. <i>The Cochrane Library</i> , 2016, , CD005336.	1.5	141
6	The health effects of ecstasy: a literature review. <i>Drug and Alcohol Review</i> , 2002, 21, 53-63.	1.1	126
7	Buprenorphine for the management of opioid withdrawal. , 2009, , CD002025.		124
8	Alpha<sub>2</sub>-adrenergic agonists for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2016, 2016, CD002024.	1.5	122
9	Substitution treatment of injecting opioid users for prevention of HIV infection. , 2008, , CD004145.		98
10	Pharmacotherapies for cannabis dependence. <i>The Cochrane Library</i> , 2014, , CD008940.	1.5	94
11	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. <i>Journal of General Internal Medicine</i> , 2006, 21, 193-195.	1.3	83
12	Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. <i>Drug and Alcohol Dependence</i> , 2004, 73, 219-226.	1.6	78
13	Buprenorphine for managing opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002025.	1.5	66
14	BRIEF REPORT: Methadone Treatment of Injecting Opioid Users for Prevention of HIV Infection. <i>Journal of General Internal Medicine</i> , 2006, 21, 193-195.	1.3	66
15	Î± <sub>2</sub> -Adrenergic agonists in opioid withdrawal. <i>Addiction</i> , 2002, 97, 49-58.	1.7	63
16	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005, 16, 67-75.	1.6	55
17	Buprenorphine for the management of opioid withdrawal. , 2006, , CD002025.		55
18	Alpha<sub>2</sub>-adrenergic agonists for the management of opioid withdrawal. , 2014, , CD002024.		44

#	ARTICLE	IF	CITATIONS
19	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. <i>Drug and Alcohol Dependence</i> , 2002, 68, 5-14.	1.6	41
20	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>The Cochrane Library</i> , 2010, , CD002022.	1.5	41
21	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. <i>Drug and Alcohol Review</i> , 2014, 33, 115-128.	1.1	41
22	Alpha2-adrenergic agonists for the management of opioid withdrawal. , 2009, , CD002024.		39
23	Pharmacotherapies for problematic psychostimulant use: a review of current research. <i>Drug and Alcohol Review</i> , 2004, 23, 203-211.	1.1	38
24	Mitigating the risk of HIV infection with opioid substitution treatment. <i>Bulletin of the World Health Organization</i> , 2013, 91, 148-149.	1.5	36
25	Supervised dosing with a long-acting opioid medication in the management of opioid dependence. <i>The Cochrane Library</i> , 2017, 4, CD011983.	1.5	36
26	Heroin users in Australia: population trends. <i>Drug and Alcohol Review</i> , 2004, 23, 107-116.	1.1	35
27	Opioid antagonists with minimal sedation for opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002021.	1.5	35
28	Pharmacotherapies for cannabis dependence. <i>The Cochrane Library</i> , 2020, 2020, CD008940.	1.5	35
29	New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. <i>Medical Journal of Australia</i> , 2021, 215, S3-S32.	0.8	34
30	The place of detoxification in treatment of opioid dependence. <i>Current Opinion in Psychiatry</i> , 2006, 19, 266-270.	3.1	27
31	Opioid antagonists with minimal sedation for opioid withdrawal. , 2009, , CD002021.		27
32	Supplementary Thiamine is Still Important in Alcohol Dependence. <i>Alcohol and Alcoholism</i> , 2013, 48, 88-92.	0.9	26
33	Is Long-Term Benzodiazepine Use a Risk Factor for Cognitive Decline? Results of a Systematic Review. <i>Journal of Addiction</i> , 2020, 2020, 1-10.	0.9	22
34	Alpha2 adrenergic agonists for the management of opioid withdrawal. , 2004, , CD002024.		18
35	Maintenance drugs to treat opioid dependence. <i>BMJ, The</i> , 2012, 344, e2823-e2823.	3.0	18
36	The management of opioid withdrawal. <i>Drug and Alcohol Review</i> , 2000, 19, 309-318.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. <i>Drug and Alcohol Review</i> , 2003, 22, 425-431.	1.1	11
38	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. , 2006, , CD002022.		10
39	Opioid antagonists with minimal sedation for opioid withdrawal. , 2006, , CD002021.		9
40	Systematic review processes and the management of opioid withdrawal. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 427-431.	0.8	5
41	The role of opioid substitution treatment in reducing HIV transmission. <i>BMJ</i> , The, 2012, 345, e6425-e6425.	3.0	5
42	Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 355-372.	0.9	5
43	Therapeutic use of cannabis: clarifying the debate. <i>Drug and Alcohol Review</i> , 1998, 17, 445-452.	1.1	3
44	Mg <sup>2+</sup> adenosine triphosphatase from cell envelopes of free-living and bacteroid forms of <i>Rhizobium lupini</i> strain NZP2257. <i>Archives of Biochemistry and Biophysics</i> , 1984, 232, 337-347.	1.4	2
45	Office based treatment with buprenorphine plus naloxone, or buprenorphine alone reduces opiate use and craving. <i>Evidence-Based Mental Health</i> , 2004, 7, 54-54.	2.2	1
46	Reply to Warnakulasuriya <i>et al</i> .. <i>Addiction</i> , 2015, 110, 1533-1534.	1.7	1
47	The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology. , 2016, , 649-659.		1
48	Which substitution pharmacotherapy is most effective in treating opioid dependence?. <i>Medical Journal of Australia</i> , 2002, 176, 493-494.	0.8	0
49	Identifying correctionsâ€”is there a better way?. <i>Addiction</i> , 2015, 110, 1207-1207.	1.7	0
50	Brief Intervention for Illicit Drug Use. , 2021, , 655-671.		0